AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33047586 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine mesoappendixectomy (main group)
Number of subjects: 127
Study 33047586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 127
Study 36000551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng, Lilii Bulbus, and Poria (GLP) supplementation
Number of subjects: 82
Study 36000551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 32845021 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient supplements (fish oil and multivitamin)
Number of subjects: 682
Study 32845021 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinutrient supplements and food‐related behavioral activation therapy (F‐BA)
Number of subjects: 682
Study 32845021 — intervention group
Group type: COMPARATOR
Intervention: Placebos
Number of subjects: 682
Study 32845021 — intervention group
Group type: COMPARATOR
Intervention: Placebos and food‐related behavioral activation therapy (F‐BA)
Number of subjects: 682
Study 34883184 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Number of subjects: 81
Study 34883184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 81
Study 34908185 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional balanced occlusion (CBO)
Number of subjects: 30
Study 34908185 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualised balanced occlusion (LBO)
Number of subjects: 30
Study 34908185 — intervention group
Group type: EXPERIMENTAL
Intervention: Masticatory performance with increased cycles
Number of subjects: 30
Study 34908185 — intervention group
Group type: EXPERIMENTAL
Intervention: Second masticatory evaluation session
Number of subjects: 30
Study 36410405 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-assisted intervention (CAI) consisting of 35-min weekly sessions over 6 weeks
Number of subjects: 104
Study 36410405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 32627064 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol combined with butorphanol
Number of subjects: 126
Study 32627064 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 126
Study 34393051 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic vision (SV)
Number of subjects: 60
Study 34393051 — intervention group
Group type: COMPARATOR
Intervention: Eyes open (EO)
Number of subjects: 60
Study 34378511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin
Number of subjects: 82
Study 34378511 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 82
Study 34378511 — intervention group
Group type: COMPARATOR
Intervention: Saline (no treatment)
Number of subjects: 82
Study 32660566 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term (6 days) supplementation of amaranth concentrate derived dietary NO3- (±400 mg)
Number of subjects: 13
Study 32660566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 34301224 — intervention group
Group type: EXPERIMENTAL
Intervention: VR + CBT (N=68)
Number of subjects: 131
Study 34301224 — intervention group
Group type: EXPERIMENTAL
Intervention: VR + CR (N=63)
Number of subjects: 131
Study 35510755 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (low intensity, moderate intensity, high intensity)
Number of subjects: 31169
Study 35510755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity statins
Number of subjects: 31169
Study 35510755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statins
Number of subjects: 31169
Study 35510755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statins
Number of subjects: 31169
Study 35510755 — intervention group
Group type: COMPARATOR
Intervention: Non-users of statins
Number of subjects: 31169
Study 35510755 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 31169
Study 34881189 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-informed pre-visit planning
Number of subjects: 0
Study 34881189 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-visit planning
Number of subjects: 0
Study 34259846 — intervention group
Group type: EXPERIMENTAL
Intervention: Video messages on COVID-19 delivered by physicians (3 videos discussing symptoms, case numbers, and social distancing guidelines)
Number of subjects: 20460
Study 34259846 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 placebo videos with generic health topics)
Number of subjects: 20460
Study 34983022 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized-load power training (IPT)
Number of subjects: 10
Study 34983022 — intervention group
Group type: COMPARATOR
Intervention: Traditional moderate-load power training (TPT)
Number of subjects: 10
Study 33089386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid 30% with ferulic peel 12% (combination peel)
Number of subjects: 60
Study 33089386 — intervention group
Group type: COMPARATOR
Intervention: Ferulic peel 12% alone (monotherapy)
Number of subjects: 60
Study 32513252 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow hemiarthroplasty (EHA)
Number of subjects: 44
Study 32513252 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 44
Study 33277302 — intervention group
Group type: EXPERIMENTAL
Intervention: AP+MDA
Number of subjects: 11
Study 33277302 — intervention group
Group type: COMPARATOR
Intervention: CSII
Number of subjects: 11
Study 33277302 — intervention group
Group type: COMPARATOR
Intervention: AP
Number of subjects: 11
Study 33893867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic 4-grade system for tear film viscosity grading
Number of subjects: 34
Study 33893867 — intervention group
Group type: COMPARATOR
Intervention: Normal playback speed
Number of subjects: 34
Study 33893867 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8-times playback speed
Number of subjects: 34
Study 32428027 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Score Card (CSC) intervention
Number of subjects: 412
Study 32428027 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 412
Study 34951063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary home trainer)
Number of subjects: 130
Study 34951063 — intervention group
Group type: COMPARATOR
Intervention: Stretching (active control)
Number of subjects: 130
Study 32098219 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-green tea (MGT)
Number of subjects: 38
Study 32098219 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-green tea (EGT)
Number of subjects: 38
Study 32098219 — intervention group
Group type: COMPARATOR
Intervention: Morning-placebo (MP)
Number of subjects: 38
Study 32098219 — intervention group
Group type: COMPARATOR
Intervention: Evening-placebo (EP)
Number of subjects: 38
Study 32098219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute EGCG administration (morning and evening in mice)
Number of subjects: 38
Study 36200646 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐dose dual‐impregnated antibiotic‐loaded cement (DIAC) including gentamicin and clindamycin
Number of subjects: 7000
Study 36200646 — intervention group
Group type: COMPARATOR
Intervention: Low‐dose single‐impregnated gentamicin antibiotic‐loaded cement (SIAC)
Number of subjects: 7000
Study 36200646 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAC
Number of subjects: 7000
Study 36200646 — intervention group
Group type: COMPARATOR
Intervention: SIAC
Number of subjects: 7000
Study 32488583 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-mediated telemedicine tools for assessing ASD risk
Number of subjects: 0
Study 35596958 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional Embolization
Number of subjects: 144
Study 35596958 — intervention group
Group type: COMPARATOR
Intervention: Intracranial Clipping
Number of subjects: 144
Study 32536106 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated carpometacarpal metacarpophalangeal immobilization splint for 6 weeks
Number of subjects: 63
Study 32536106 — intervention group
Group type: COMPARATOR
Intervention: Nonsplint group (oral information about daily activities)
Number of subjects: 63
Study 36175902 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy
Number of subjects: 90
Study 36175902 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 90
Study 33675139 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational intervention for Alzheimer's disease
Number of subjects: 0
Study 33675139 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical methods for estimating treatment effects
Number of subjects: 0
Study 32903263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatiguing task (Stroop task)
Number of subjects: 9
Study 32903263 — intervention group
Group type: COMPARATOR
Intervention: Control task (documentary watching)
Number of subjects: 9
Study 32040383 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online interventions for hazardous alcohol use
Number of subjects: 1711
Study 32040383 — intervention group
Group type: EXPERIMENTAL
Intervention: High BIDR scores
Number of subjects: 1711
Study 32040383 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct measures of alcohol use
Number of subjects: 1711
Study 33066334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutraceutical containing phytosterols (800 mg) and red yeast rice (5 mg of monacolins), niacin (27 mg), and policosanols (10 mg)
Number of subjects: 88
Study 33066334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 33066334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutraceutical
Number of subjects: 88
Study 37338553 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS model
Number of subjects: 85
Study 37338553 — intervention group
Group type: EXPERIMENTAL
Intervention: EOB-MRI model
Number of subjects: 85
Study 37338553 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS-EOB model
Number of subjects: 85
Study 34333777 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination program
Number of subjects: 10614
Study 34333777 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 10614
Study 34928687 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic Healing Arts Retreat
Number of subjects: 109
Study 33649888 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive (n=41)
Number of subjects: 82
Study 33649888 — intervention group
Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit (n=41)
Number of subjects: 82
Study 36341846 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training program (UFOVT) for 45 sessions over 2.5 years
Number of subjects: 0
Study 36341846 — intervention group
Group type: COMPARATOR
Intervention: Computerized games (control group) for 45 sessions over 2.5 years
Number of subjects: 0
Study 35804370 — intervention group
Group type: EXPERIMENTAL
Intervention: REP + Coaching + Facilitation
Number of subjects: 169
Study 35804370 — intervention group
Group type: COMPARATOR
Intervention: REP alone
Number of subjects: 169
Study 35804370 — intervention group
Group type: EXPERIMENTAL
Intervention: REP + Facilitation
Number of subjects: 169
Study 35804370 — intervention group
Group type: EXPERIMENTAL
Intervention: REP + Coaching
Number of subjects: 169
Study 34003662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month DAPT
Number of subjects: 509
Study 34003662 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 509
Study 32216764 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating SOS intervention (four online sessions)
Number of subjects: 0
Study 35554955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eltrombopag (50 mg daily)
Number of subjects: 92
Study 35554955 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous rhTPO (15000U daily)
Number of subjects: 92
Study 32867882 — intervention group
Group type: EXPERIMENTAL
Intervention: FDPIR diet that met Dietary Guidelines for Americans (DGA)
Number of subjects: 13
Study 32867882 — intervention group
Group type: COMPARATOR
Intervention: Typical FDPIR diet
Number of subjects: 13
Study 35970302 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC; salvage chemoimmunotherapy followed by high-dose therapy with autologous stem cell rescue for responders)
Number of subjects: 0
Study 32529884 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LR3 + KI3
Number of subjects: 29
Study 32529884 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at LR3 and sham location
Number of subjects: 29
Study 34194041 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-CVac(PYR) (high dose, 2 × 10^5 PfSPZs)
Number of subjects: 35
Study 34194041 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-CVac(PYR) (low dose, 5.12 × 10^4 PfSPZs)
Number of subjects: 35
Study 34194041 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ-CVac(CQ)
Number of subjects: 35
Study 34194041 — intervention group
Group type: COMPARATOR
Intervention: Infectivity control (homologous CHMI)
Number of subjects: 35
Study 34194041 — intervention group
Group type: COMPARATOR
Intervention: Infectivity control (heterologous CHMI)
Number of subjects: 35
Study 35085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemiplegia (LH)
Number of subjects: 35
Study 35085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemiplegia (RH)
Number of subjects: 35
Study 35085303 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied (AB)
Number of subjects: 35
Study 33613861 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily
Number of subjects: 30
Study 33211894 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for amblyogenic risk factors
Number of subjects: 299
Study 34115061 — intervention group
Group type: EXPERIMENTAL
Intervention: Osseodensification
Number of subjects: 24
Study 34115061 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling
Number of subjects: 24
Study 35067664 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked group (120 eyes)
Number of subjects: 240
Study 35067664 — intervention group
Group type: COMPARATOR
Intervention: Control group (120 eyes)
Number of subjects: 240
Study 33279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine (Phase 1)
Number of subjects: 720
Study 33279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine, amisulpride, or clozapine (Phase 2)
Number of subjects: 720
Study 33279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine or another SGAs not previously used (Phase 3B)
Number of subjects: 720
Study 33279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine extended treatment or modified electroconvulsive therapy (Phase 3A)
Number of subjects: 720
Study 33279374 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic follow-up phase
Number of subjects: 720
Study 35640246 — intervention group
Group type: COMPARATOR
Intervention: Postoperative mFOLFOX6 (12 courses of intravenous oxaliplatin [85 mg/m2] with L-leucovorin [200 mg/m2] followed by 5-fluorouracil [400 mg/m2, bolus and 2400 mg/m2, continuous infusion, repeated every 2 weeks])
Number of subjects: 48
Study 35640246 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative mFOLFOX6 (six courses each preoperatively and postoperatively)
Number of subjects: 48
Study 35640246 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative mFOLFOX6
Number of subjects: 48
Study 35640246 — intervention group
Group type: COMPARATOR
Intervention: Postoperative mFOLFOX6
Number of subjects: 48
Study 32778788 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 35041261 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 96
Study 35041261 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam
Number of subjects: 96
Study 33784467 — intervention group
Group type: EXPERIMENTAL
Intervention: VAULT treatment with brief utterances (four words or fewer)
Number of subjects: 19
Study 33784467 — intervention group
Group type: EXPERIMENTAL
Intervention: VAULT treatment with extended utterances (five words or more)
Number of subjects: 19
Study 33784467 — intervention group
Group type: EXPERIMENTAL
Intervention: CART analysis for treatment responders
Number of subjects: 19
Study 32093785 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 500
Study 32093785 — intervention group
Group type: COMPARATOR
Intervention: Placebo electroacupuncture (vaccaria seeds)
Number of subjects: 500
Study 33764102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal amphetamine administration
Number of subjects: 40
Study 33764102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33486403 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based palliative approach (HPA)
Number of subjects: 78
Study 33486403 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 78
Study 35912731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 132
Study 35912731 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 132
Study 33514365 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 2068
Study 33514365 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-alcoholic fatty liver disease (NAFLD)
Number of subjects: 2068
Study 33514365 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT volume
Number of subjects: 2068
Study 33514365 — intervention group
Group type: COMPARATOR
Intervention: Control group (without MetS)
Number of subjects: 2068
Study 35324317 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic standard gastrectomy (LSG)
Number of subjects: 580
Study 35324317 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel node navigation surgery (LSNNS)
Number of subjects: 580
Study 35684105 — intervention group
Group type: EXPERIMENTAL
Intervention: carbonated caffeinated beverage
Number of subjects: 24
Study 35684105 — intervention group
Group type: EXPERIMENTAL
Intervention: caffeinated beverage
Number of subjects: 24
Study 35684105 — intervention group
Group type: COMPARATOR
Intervention: control beverage
Number of subjects: 24
Study 33589758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (systolic BP target of 120 mm Hg)
Number of subjects: 1206
Study 33589758 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment (systolic BP target of 140 mm Hg)
Number of subjects: 1206
Study 34301646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone alongside standard antiviral treatment with aciclovir
Number of subjects: 90
Study 34301646 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone (control)
Number of subjects: 90
Study 32273271 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine U300
Number of subjects: 176
Study 32273271 — intervention group
Group type: COMPARATOR
Intervention: Glargine U100
Number of subjects: 176
Study 616880758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Number of subjects: 402
Study 616880758 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 402
Study 35805647 — intervention group
Group type: EXPERIMENTAL
Intervention: BA + Cr
Number of subjects: 20
Study 35805647 — intervention group
Group type: COMPARATOR
Intervention: BA + PL
Number of subjects: 20
Study 34265791 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (2.5 mg/12 h) in combination with morphine
Number of subjects: 41
Study 34265791 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 41
Study 35428993 — intervention group
Group type: EXPERIMENTAL
Intervention: RIG (Radiologically Inserted Gastrostomy)
Number of subjects: 42
Study 35428993 — intervention group
Group type: COMPARATOR
Intervention: PEG (Percutaneous Endoscopic Gastrostomy)
Number of subjects: 42
Study 35428993 — intervention group
Group type: EXPERIMENTAL
Intervention: RIG
Number of subjects: 42
Study 35428993 — intervention group
Group type: COMPARATOR
Intervention: PEG
Number of subjects: 42
Study 34721645 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology (30 minutes, 3 times a week for 4 weeks)
Number of subjects: 47
Study 34721645 — intervention group
Group type: COMPARATOR
Intervention: Sham foot massage (30 minutes, 3 times a week for 4 weeks)
Number of subjects: 47
Study 35514234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex education program (two sessions a week for two weeks, 90 min each)
Number of subjects: 72
Study 35514234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex education program
Number of subjects: 72
Study 35514234 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 33298162 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Stroke Specialist Vocational Rehabilitation (ESSVR) plus usual care (UC)
Number of subjects: 760
Study 33298162 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 760
Study 33298162 — intervention group
Group type: EXPERIMENTAL
Intervention: ESSVR plus UC
Number of subjects: 760
Study 33298162 — intervention group
Group type: COMPARATOR
Intervention: UC alone
Number of subjects: 760
Study 33259892 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 0
Study 33259892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib
Number of subjects: 0
Study 33259892 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 0
Study 32331082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40 mg/day or 80 mg/day)
Number of subjects: 271
Study 36399919 — intervention group
Group type: EXPERIMENTAL
Intervention: Paily Obstetric Forceps (POF)
Number of subjects: 100
Study 33559971 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurycoma longifolia 600 mg/day for two weeks
Number of subjects: 32
Study 33559971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 35661898 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted home visits by community nurses post treatment administration
Number of subjects: 25
Study 35661898 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular contact with community nursing services
Number of subjects: 25